Physician profile
Michael K Dragan
NPI 1053370791
$2,121.00
in general payments reported to CMS, 2019-2025
25 companies · $20.50 in 2025
The $20.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $347 · 2021: $564 · 2022: $236 · 2023: $470 · 2024: $163 · 2025: $20.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.37 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $211.79 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $191.99 | 2020-2024 | Otezla, Repatha |
| Abbott Laboratories | $184.45 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $161.91 | 2019-2020 | |
| Pfizer INC. | $124.64 | 2019-2024 | |
| Lilly USA, LLC | $106.06 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $93.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.14 | 2021 | |
| Amarin Pharma, INC. | $65.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.27 | 2019-2023 | |
| Smith+Nephew, INC. | $50.35 | 2024 | Collagenase Santyl |
| Horizon Therapeutics Plc | $50.18 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $44.29 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $27.30 | 2019 | |
| Astellas Pharma US INC | $25.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.14 | 2022 | |
| Tris Pharma INC | $23.44 | 2024 | Dyanavel Xr |
| Ibsa Pharma INC. | $17.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.89 | 2021 | |
| Aytu Biopharma, INC. | $14.71 | 2019 | |
| Allergan, INC. | $13.50 | 2019 | |
| Merck Sharp & Dohme LLC | $12.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dragan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.